| | TPN with Gl (n = 23) | TPN without Gl (n = 20) | P-value |
|---|
Age (years) | 34.2 ± 14.7 | 40.4 ± 15.2 | 0.18 |
Male/Female | 19/4 | 18/2 | 0 |
Weight (Kg) | 77.3 ± 11.3 | 81.9 ± 11.1 | 0.19 |
SAPS | 35.8 ± 9.5 | 31.4 ± 13.5 | 0.27 |
APACHE 2 | 19.2 ± 3.2 | 15.1 ± 9.3 | 0.12 |
APACHE 3 | 48.3 ± 18.3 | 36.1 ± 18.3 | 0.06 |
ISS | 31.4 ± 12.3 | 31.6 ± 12.6 | 0.96 |
Previous surgery | 8 | 12 | 0.43 |
Previous shock | 6 | 4 | 0.73 |
SOFA pretreatment | 7 ± 3.7 | 7 ± 3 | 0.96 |
TPN beginning (days) | 4.7 ± 3.1 | 4.3 ± 2.1 | 0.67 |
TPN duration | 14 (8 to 19) | 14.5 (8 to 23) | 0.43 |
Norepinephrine | 0.05 ± 0.1 | 0.2 ± 0.6 | 0.44 |
Pretreat. infection | 11 | 9 | 0.98 |
SOFA postreatment | 6.3 ± 3.4 | 6.8 ± 4.4 | 0.69 |
- Data are presented as mean ± SD; number of patients or median (25th to 75th percentile).
- SAPS, Simplified Acute Physiology Score; APACHE, Acute Physiology and Chronic Health Evaluation; ISS, Injury Severity Score; Previous surgery, number of patients that required surgery before randomization; Previous shock, number of patients who presented a hemorrhagic shock before randomization; SOFA pretreatment, Sequential Organ Failure Assessment before treatment; TPN beginning, Number of days since hospital admission before the patients were included in the study; TPN duration, Total duration of the TPN in days; Norepinephrine, Medium dose of norepinephrine in μg × Kg-1 × minute-1 during the five days of the treatment; Pretreat infection, Number of patients with an infection before the randomization; SOFA postreatment, Sequential Organ Failure Assessment after treatment (Day 6).
